Table 1.
Demographic and clinical characteristics of HIV-negative participants and neurophysiologically normal and HAND HIV-positive participants.
| HIV-positive | ||||
|---|---|---|---|---|
| HIV− | NP-nml | HAND (ANI– MND) | *P | |
| N | 34 | 19 | 15 (9 ANI–6 MND) | |
| Age year (mean, SD) | 44 (13) | 42.8 (8.8) | 44.0 (12.2) | 0.75 |
| Sex Male – N (%) | 30 (88%) | 17 (89%) | 14 (93%) | 0.69 |
| Race/ethnicity white – N (%) | 21 (62%) | 12 (63%) | 11 (73%) | 0.28 |
| Education-year mean (SD) | 14 (1.9) | 13 (2.6) | 14 (2.6) | 0.37 |
| Months between visits – median (IQR) | NA | 17.8 (7.0–34.3) | 14.5 (7.0–25.3) | 0.29 |
| Current CD4 – median (IQR) | ND | 628 (462–796) | 658 (442–876) | 0.85 |
| Nadir CD4 – median (IQR) | NA | 215 (180–300) | 240 (197–356) | 0.46 |
| Duration HIV mos – median (IQR) | NA | 123 (40.6–198) | 72.3 (24.3–172) | 0.37 |
| Current ART mos– median (IQR) | NA | 16.5 (7.8–24.3) | 12.6 (6.9–35.7) | 0.74 |
ANI, asymptomatic neurocognitive impairment; ART, antiretroviral therapy; HAND, HIV-associated neurocognitive disorders; MND, mild neurocognitive disorder; NA, not applicable; ND, not determined; NP-nml, neuropsychologically normal.
*
P value is for NP-nml versus HAND.